Piramal Pharma points to early recovery signs after seeing red in Q3
The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹2,140 crore, and slipping to a loss of ₹136 crore from a net profit of ₹4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal.
The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹2,140 crore, and slipping to a loss of ₹136 crore from a net profit of ₹4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
